drugset / Trial / NCT00636246

A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.

NCT00636246

Phase 2 Completed 510 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.

Timeline

Start
2004-06
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sertraline Small molecule 150 mg Oral
Subject [S,S]-Reboxetine Unknown 2 mg Oral
Subject [S,S]-Reboxetine Unknown 4 mg Oral
Subject [S,S]-Reboxetine Unknown 6 mg Oral